The official record contains a limited human signal and substantial nonclinical literature, but the exact form, dosage form, route, duration and safety questions remain unresolved.
FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.
Unlike several other subjects in the hearing, BPC-157 was not a zero-human-data record. FDA reviewed a small randomized ulcerative-colitis study and nonclinical gastrointestinal findings.
FDA briefing pp. 26–32The evidence did not establish the safety or effectiveness of both chemical forms across the nominated dosage forms and routes, and it did not resolve long-term treatment.
FDA briefing pp. 39–46The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
Only named, source-reconciled speaker moments that were checked against the recording appear here. Statements remain attributed arguments unless the underlying evidence was independently established; no machine-caption wording is published as a quotation.
Board-certified urologist; fellowship-trained in male fertility, microsurgery and sexual medicine
Verify credentialsTatem challenged the use of research-use-only certificates as representative of material sourced for human-use compounding. His point was that an uncontrolled research market and a licensed pharmacy supply chain should not be treated as the same product-quality system.
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsLurie said CSPI opposed adding all seven substances. He argued that the FDA criteria had not been met, that compounded products could create consumer risks, and that listing could weaken incentives for development through the standard drug-approval pathway.
The testimony identifies a real distinction between research reagents and material intended for human use. The hearing record did not independently establish that a compliant supply chain had already solved the exact identity, impurity and finished-product questions for either nominated form.
FDA considered both BPC-157 free base and BPC-157 acetate not well characterized from a physical and chemical perspective.
FDA Day 1 presentation · 03:14:38The critique supports tighter sourcing and release controls. It does not, by itself, characterize the exact nominated substances or a finished compounded preparation.
The favorable majority appears to have given weight to the distinction between bulks-list eligibility and drug approval, plus the possibility of a more accountable supply chain. FDA’s review asked whether the exact forms were adequately characterized and supported for the nominated injectable use; it concluded they were not.
Editorial inference from the hearing record—not an attributed rationale for every voterThese are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
FDA discussed a randomized, double-blind, placebo-controlled study in 53 people with mild-to-moderate ulcerative colitis; 46 completed two weeks of BPC-157 or placebo enema treatment.
The evidence was available as a meeting abstract with limited methodological detail. The studied enema was not the same dosage form as the nominated rectal suppository, and it did not address the nominated oral, subcutaneous, nasal or transdermal products.
FDA described gastrointestinal and wound-related effects in rodent models, including colonic-fistula and gastrointestinal-injury experiments.
FDA said dose-response relationships were not established, molecular targets were unidentified and mechanisms remained poorly understood. Nonclinical findings do not establish effectiveness in people with ulcerative colitis.
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | limited | A 53-subject randomized enema study was described in a meeting abstract; detail and duration were limited. | Briefing pp. 26–28, 53 |
| Nonclinical evidence | indirect | Rodent gastrointestinal and injury models were identified, but translation to the nominated compounded products is unresolved. | Briefing pp. 29–32 |
| Exact-form match | contested | Many cited studies did not clearly identify free base versus acetate. The withdrawn nominations were internally inconsistent. | Briefing pp. 7–12, 29 |
| Nominated-route match | limited | Rectal enema data were identified; the nominated dosage forms included oral, SC, nasal, rectal suppository and transdermal products. | Briefing pp. 7–8, 26–28 |
| Evaluated-use match | limited | The short ulcerative-colitis study matched the evaluated condition, but did not resolve long-term effectiveness. | Briefing pp. 25–28 |
| Product characterization | limited | FDA considered both forms not well characterized and identified naming, impurity and finished-product control gaps. | Briefing pp. 8–21 |
| Human safety | limited | Short rectal exposures were described with limited monitoring; FDA found long-term safety information insufficient. | Briefing pp. 39–45 |
| Historical compounding use | limited | FDA found the available information too limited to understand historical compounding use. | Briefing pp. 21–25 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
Controlled human trials identifying the exact chemical form, dosage form and route
Long-term safety data appropriate to a chronic ulcerative-colitis treatment
Validated identity, impurity, aggregation and finished-product specifications
KPV’s official-record case is primarily mechanistic and nonclinical. FDA said it found no human administration or exposure data by any route.
Open dossierDay 1The central technical issue is identity: FDA treated the seven-amino-acid TB-500 fragment as distinct from full-length thymosin beta-4 and found no direct human TB-500 evidence.
Open dossierDay 1The scientific premise is mitochondrial and metabolic, but FDA said it found no clinical study or human-administration evidence and no adequate nonclinical toxicity package.
Open dossierFree newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.